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Introduction
Glycaemic control is fundamental in the management
of diabetes. The goal of diabetic therapy is to achieve
fasting and postprandial glucose concentrations and
haemoglobin A1c (HbA1c) as close to normal as pos-
sible without hypoglycaemia (1). Postprandial hyper-
glycaemia is an early abnormality in the progression of
type 2 diabetes and is problematic in patients with
fasting hyperglycaemia (2). According to Monnier
et al. (3), the contribution of postprandial blood glu-
cose (PPBG) excursions to overall hyperglycaemia
(represented by HbA1c) is predominant in patients
with moderate hyperglycaemia (HbA1c < 7.3%),
whereas the contribution of fasting hyperglycaemia is
greater and increases with worsening overall glucose
control (HbA1c > 8.4%). These observations were
expanded by Monnier et al. (4) who found that as
HbA1c levels increase with duration of type 2 diabetes
in patients not treated with insulin, diurnal glycaemic
control is lost in progressive steps – ﬁrst during post-
prandial periods, then in the morning period (during
the ‘dawn phenomenon’ of rising blood glucose), and
then in the nocturnal fasting period. Therefore, as gly-
caemic control improves with basal-insulin treatment,
PPBG coverage is needed to achieve or to keep HbA1c
at < 7%. In addition to being a marker for the onset
of type 2 diabetes, elevated PPBG is an independent
risk factor for the development of micro- and macro-
vascular complications and affects the morbidity and
mortality associated with long-term hyperglycaemia
(5–7).
According to the American Diabetes Association
(1), individuals with premeal glucose values within
the target but not meeting HbA1c targets should
monitor for 1–2 h for PPBG and treat to reduce
PPBG values to < 10 mmol⁄l. The International
Diabetes Federation (8) recommends treating both
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SUMMARY
Aim: To compare the 2-h postprandial blood glucose (PPBG) excursion following a
standard test meal in insulin-requiring patients with diabetes treated twice daily
with human insulin mix 50 vs. insulin lispro mix 50 (LM50). Methods: This was a
multicentre, randomised, open-label, crossover comparison of two insulin treat-
ments for two 12-week treatment periods in 120 Chinese patients. One- and 2-h
PPBG and excursion values were obtained following a standardised test meal. Fast-
ing blood glucose (FBG), haemoglobin A1c (HbA1c), insulin dose, rate of hypo-
glycaemia and safety data were obtained. A crossover analysis using SAS Proc
MIXED was employed. Results: Mean 2-h PPBG excursion decreased from
6.32 ± 3.07 mmol⁄l at baseline to 3.47 ± 2.97 mmol⁄l at end-point in the LM50
group, and from 6.31 ± 2.88 at baseline to 5.02 ± 3.32 mmol⁄l at end-point in
the human insulin mix 50 group (p < 0.001). Two-hour PPBG (p = 0.004) and 1-h
PPBG excursion (p < 0.001) were signiﬁcantly lower with LM50 as compared with
human insulin mix 50. Both treatment groups were equivalent for HbA1c control,
1-h PPBG and insulin dose requirements. Mean FBG was higher with LM50 than
with human insulin mix 50 (p = 0.023). The overall incidence of treatment-emer-
gent adverse events and hypoglycaemia rate per 30 days were similar between
treatment groups. Conclusions: Insulin lispro mix 50 provided better postprandial
glycaemic control compared with human insulin mix 50 while providing the conve-
nience of injecting immediately before meals. Both treatments were generally well
tolerated by all randomly assigned patients.
What’s known
Premixed basal and prandial insulins provide
relatively convenient and consistent dosing. Human-
insulin mixtures, widely prescribed in China, have
slower onset and longer duration of action than
rapid acting insulin analogues such as insulin lispro.
Several clinical trials have consistently reported
better postprandial blood glucose (PPBG) control
with ﬁxed mixtures containing insulin lispro.
What’s new
For the ﬁrst time, rapid-acting insulin lispro and
basal insulin lispro protamine suspension (ILPS) in a
1 : 1 ratio (LM50) was investigated against human
insulin mix 50 in a twice-a-day regimen in Chinese
patients with diabetes. LM50 demonstrated better
postprandial but equivalent overall glycaemic
control compared with human insulin mix 50
following a high carbohydrate meal representing a
typical Chinese breakfast.
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level to achieve and maintain optimum glycaemic
control, targeting PPBG < 7.8 mmol⁄l.
Thus, PPBG measurement and control are impor-
tant in overall diabetes management. PPBG proﬁle is
determined by multiple factors including carbohy-
drate absorption, insulin and glucagon secretion, and
their coordinated glucose metabolism in the liver and
peripheral tissues. Abnormalities in insulin and gluca-
gon secretion, hepatic glucose uptake, suppression of
the hepatic glucose production, and peripheral glu-
cose uptake associated with type 1 and type 2 diabetes
contribute to higher and more prolonged PPBG
excursions than in individuals without diabetes. The
timing of PPBG measurement is crucial to acquiring
the best information. As the complete absorption of
food from a typical meal takes 5–6 h, measurement of
plasma glucose 2 h after the start of a meal approxi-
mates the peak PPBG value and provides a reasonable
assessment of postprandial hyperglycaemia (2).
This study was conducted in China, where the
number of people with diabetes or prediabetes has
increased dramatically over the past two decades
because of the growing economy and improved stan-
dard of living that has resulted in the consumption of
a higher-calorie, higher-fat diet with more processed
foods and a parallel reduction in physical activity (9).
A typical Chinese diet, including rice and wheat
breads, consists of approximately 58% carbohydrates,
which can induce high PPBG, especially postbreakfast
(10). Optimal post-prandial glycaemic control for
these high carbohydrate meals may require higher
doses of rapid-acting insulin than often used in other
economic and cultural environments.
Evaluation of intensive insulin regimens has sug-
gested that to achieve optimal glycaemic control,
therapy with at least two insulin formulations differ-
ing in their time-activity proﬁles is required. Treat-
ment with conventional human insulin mixtures,
however, may result in a non-physiological blood
glucose response to a meal with high PPBG excur-
sions, an extended period of hyperglycaemia and the
risk of hypoglycaemia later in the day (11). Rapid-
acting insulin analogues (insulin lispro, insulin aspart
and insulin glulisine) premixed with basal compo-
nents overcome many of the limitations of regular
insulin therapies because of faster onset and shorter
duration. In several studies, these analogue formula-
tions provided better or equivalent postprandial gly-
caemic control with a reduced risk of hypoglycaemia
compared with premixed human insulin along with
greater ﬂexibility and convenience of injecting imme-
diately before meals (11–14).
Insulin lispro mix 50 (LM50: Humalog
  Mix50 ,
Eli Lilly and Company, Indianapolis, IN) contains
50% insulin lispro and 50% insulin lispro protamine
suspension (ILPS). Insulin lispro, the rapid-acting
component, addresses the insulin requirements
related to the morning and evening meals, and ILPS
provides basal insulin throughout the day and also
during the night.
In this study, we compared LM50 with human insu-
lin mix 50 (50% regular human insulin, 50% human
insulin isophane suspension; Novolin
  50, Novo Nor-
disk, Bagsværd, Denmark) for the control of 2-h PPBG
excursion following a standard test meal in Chinese
patients with type 1 or type 2 diabetes. In addition,
FBG, 1- and 2-h PPBG, 1-h PPBG excursion, HbA1c,
insulin dose requirements and safety of the two for-
mulations were also assessed.
Methods
Study design
This study was a multicentre (three centres in China),
randomised, open-label, 2-sequence, 2-period, cross-
over trial in patients with type 1 or type 2 diabetes
treated twice daily with human insulin mix 50 vs.
LM50. Standard test meals were administered to com-
pare these insulin treatments for their effect on 2-h
PPBG excursion (Figure 1). The 2-h PPBG excursion
was the blood glucose measurement 2 h after the start
of the test meal minus the FBG measurement immedi-
ately prior to the test meal. Secondary objectives
included FBG prior to the test meal, 1-h and 2-h
PPBG and 1-h PPBG excursion following the test
meal, changes in insulin dose requirements through-
out the study and HbA1c at treatment end-points.
The study protocol was approved by the local Medical
Research Ethics Committee of all participating centres.
The participants signed an informed consent docu-
ment to participate in the study in accordance with
the Declaration of Helsinki and good clinical practice
guidelines.
Patients and study conduct
One hundred and twenty patients of Chinese origin,
with either type 1 or type 2 diabetes (aged 18–
70 years) were recruited. Criteria for inclusion were
the diagnosis of diabetes of at least 2 months’ dura-
tion, an HbA1c of 1.1–1.7 times the upper limit of
the normal reference range (inclusive) and signed
informed consent. The patients should have been
using human insulin mix 50 or human insulin mix
30 twice daily as the only pharmacological treatment
for their diabetes for at least 2 months prior to the
enrolment in the study.
Individuals were ineligible if they had used oral
antidiabetic agents within 60 days prior to recruit-
ment, received a total daily dose of insulin
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severe hypoglycaemia (requiring external assistance)
within preceding 6 months, a body mass index >
35 kg⁄m
2, serum creatinine more than the upper
limit of normal, a history of class III⁄IV cardiac
disease or renal transplantation, obvious clinical
symptoms of liver disease, hepatitis, alanine trans-
aminase more than three times the upper limit,
known allergy to insulin or excipients contained
in insulin products, or undergoing therapy for a
malignancy other than basal cell or squamous-cell
skin cancer. Female patients who were not practising
a birth control method or were pregnant or breast-
feeding were also excluded.
Enrolled patients were randomised to two groups
in a 1 : 1 ratio, with 60 patients in each sequence
group. One sequence group received 12 weeks of
twice-daily treatment with LM50, followed by
12 weeks of twice-daily treatment with human insu-
lin mix 50 (sequence 1). The other group received
the reverse treatment of the sequence 1 (sequence 2).
At visit 1, patients were evaluated for their signiﬁ-
cant medical history including duration of diabetes,
duration of insulin treatment, previous therapy for
diabetes, current drug therapy and any pre-existing
conditions to ensure consistency of inclusion and
exclusion criteria. From visit 2 through visit 8, the
efﬁcacy and safety of LM50 compared with human
insulin mix 50 in the treatment of diabetes were
evaluated. Test meals were administered to patients
at visits 2, 5 and 8 (Figure 1).
All insulin injections were given subcutaneously
using insulin pens (HumaPen Ergo
 , Eli Lilly, for
LM50; NovoPen
  3, Novo Nordisk, for human insu-
lin mix 50). Throughout the study, investigators
adjusted the morning and evening dose of human
insulin mix 50 or LM50 in accordance with the indi-
vidual needs of the patient. LM50 and human insulin
mix 50 may be administered at equivalent doses;
however, patients were monitored for changes in
insulin requirements following conversion between
the two mixtures. Patients were educated regarding
the time of insulin action for each insulin mixture.
Human insulin mix 50 was administered within
30 min before the morning and evening meals.
LM50 was administered within 15 min prior to the
morning and evening meals. Patients performed self-
blood glucose monitoring (at least daily testing of
morning fasting serum glucose and once- or twice-
weekly testing of PPBG was recommended).
The primary efﬁcacy measure in this study was to
compare the 2-h PPBG excursion after the test meal
at visit 5 (study midpoint) and 8 (study end-point).
Additional efﬁcacy variables included 1- and 2-h
PPBG, 1-h PPBG excursion from the test meal, FBG,
HbA1c and insulin-dose requirements.
Patients consumed the standard test meal that
comprised of 90 g noodles, representing a typical
Chinese breakfast. The total caloric content of the
standard test meal was 460 kcal (carbohydrates
65%, fat 20%, protein 9.3% and others 5.7%).
Patients ate the same test meal at the same time
of day at each of these visits, and the content of
the test meal was identical for all patients at all
study sites.
Patients were monitored for safety closely through-
out the trial. Participants recorded any episodes of
hypoglycaemia, deﬁned as blood glucose <
3.5 mmol⁄l, accompanied by subjective symptoms or
identiﬁed by signs considered to represent hypoglyca-
emia noted by an observer. At each patient visit, the
rate of hypoglycaemia was computed as the number
Figure 1 Study design: (a) lead-in period, (b) screening visit, (c) ±3 days and (d) ±7 days
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30 days (episodes since previous visit⁄patient⁄
30 days). Adverse events, concomitant therapies
taken, laboratory data and vital signs of all rando-
mised patients were also recorded at regular inter-
vals.
Statistical analyses
With an expected dropout rate of not > 15% after
randomisation, at least 100 patients were expected to
complete the study. The sample size for this study
was selected to provide at least 80% power to achieve
statistical signiﬁcance if the true treatment difference
was at least 1.0 mmol⁄l and was calculated using a
two-sided one-sample t-test at a = 0.05.
Efﬁcacy and safety analyses were conducted on the
modiﬁed intent-to-treat population that included all
patients randomised to one of the sequence groups
and had received at least one dose of insulin therapy.
In general, descriptive summary statistics was
included for categorical and continuous variables. All
comparisons were performed using two-tailed tests
with a nominal signiﬁcance level of 0.05.
The efﬁcacy variables (2-h PPBG excursion, 1-h
PPBG excursion, 2-h PPBG, 1-h PPBG, FBG and
HbA1c) were analysed using the mixed model, with
ﬁxed effects for sequence, period, treatment, base-
line FBG as a covariate, which was only adjusted
for the analysis of PPBG excursion, and patient
nested within sequence as a random effect (15).
Analysis for binary response data suitable for the
two-period crossover design was conducted using
Prescott’s test (16). For patients with a particular
measurement missing at end-point (at last sched-
uled visit of each period), the most recently
observed datum from the same treatment period
was used in the analysis.
Results
Demographic and baseline characteristics
Of the 142 patients screened, 120 patients were
included in the study, with 60 randomised to each
sequence group. Table 1 summarises the demo-
graphic and baseline characteristics for all rando-
mised patients (108 with type 2 and 12 with type 1
diabetes). One hundred and ﬁfteen patients com-
pleted the study (57 in sequence group 1 and 58 in
sequence group 2). Figure 2 presents a schematic
representation of patient disposition in the study.
2-h postprandial blood glucose excursion
Mean 2-h PPBG excursion decreased from 6.32 ±
3.07 mmol⁄l at baseline to 3.47 ± 3.00 mmol⁄la t
end-point in the LM50 group (a reduction of
2.89 ± 3.27 mmol⁄l), and from 6.31 ± 2.88 mmol⁄l
at baseline to 5.02 ± 3.32 mmol⁄l at end-point in
the human insulin mix 50 group (a reduction of
1.32 ± 3.38 mmol⁄l). The decrease in 2-h PPBG was
signiﬁcantly greater with LM50 when compared to
that with human insulin mix 50 (p < 0.001).
Analysis of 2-h PPBG excursion at end-point by
sequence group for each treatment period showed
patients on LM50 had statistically signiﬁcantly lower
Table 1 Demographic and baseline characteristics (mean ± SD) for all randomised patients by treatment sequence
Variable
Statistic
Sequence group 1,
lispro ﬁ human
N =6 0
Sequence group 2,
human ﬁ lispro
N =6 0
Overall
N = 120
Gender n (%)
Male 22 (37%) 26 (43%) 48 (40%)
Female 38 (63%) 34 (57%) 72 (60%)
Age (years) 54.3 ± 10.1 57.2 ± 8.6 55.7 ± 9.5
Body mass index (kg⁄m
2) 24.5 ± 2.6 24.4 ± 2.8 24.5 ± 2.7
Type of diabetes n (%)
Type 1 6 (10%) 6 (10%) 12 (10%)
Type 2 54 (90%) 54 (90%) 108 (90%)
Duration of diabetes (months) 142.2 ± 75.5 131.8 ± 73.0 137.0 ± 74.1
Duration of insulin treatment (months) 42.8 ± 55.9 41.2 ± 48.2 42.0 ± 52.0
HbA1c (%) 8.10 ± 1.38 8.03 ± 1.22 8.07 ± 1.30
Fasting blood glucose (mmol⁄l) 9.75 ± 3.22 9.35 ± 2.93 9.55 ± 3.07
N, sample size; n, number of patients; HbA1c, haemoglobin A1c.
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ment differences of similar magnitude at the end of
each treatment period indicate no carryover between
periods (Figure 3).
Blood glucose
Figure 4 compares blood-glucose values at baseline
and treatment end-points. Except 1-h PPBG, all
other measurements were observed to be signiﬁcantly
different between treatment groups. The mean FBG
was higher in patients on LM50 than in those on
human insulin mix 50 (p = 0.023), whereas, 2-h
PPBG (p = 0.004) and 1-h PPBG excursion
(p < 0.001) were lower with LM50 than with human
insulin mix 50.
Haemoglobin A1c
The two treatments provided equivalent mean
HbA1c values (p = 0.581) and mean change from
baseline HbA1c values (p = 0.456) at treatment end-
points. Mean HbA1c was 7.59% (decreased 0.48%
from baseline) with LM50 and was 7.61% (decreased
0.46% from baseline) with human insulin mix 50.
Insulin dose requirement
The insulin doses were similar in both treatment
groups, at each visit and end-point, for morning,
evening and total doses. The change from baseline in
insulin dose between treatment groups was not sig-
niﬁcantly different.
At baseline, patients were treated with either
human insulin mix 50 or human insulin mix 30⁄70,
at means of 0.316 units⁄kg for the morning dose and
0.272 units⁄kg for the evening dose. At study end-
point, patients were administered means of
0.364 units⁄kg morning dose and a 0.336 units⁄kg
evening dose for both treatment groups. The mean
total dose administered at each visit slightly increased
Figure 2 Patient disposition: (a) reason for discontinuation⁄non-compliance, (b) reason for discontinuation⁄adverse
events and (c) reason for discontinuation⁄personal conﬂict or other patient decision
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Figure 3 Mean 2-h postprandial blood glucose (PPBG) excursion at baseline and following treatment with insulin lispro
mix 50 and human insulin mix 50, at end-point, by sequence group for each period, for all randomly assigned patients
receiving at least one dose. *Statistically signiﬁcant difference between sequence group 1 and sequence group 2 in period 1,
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(0.663 units⁄kg to 0.699 units⁄kg for LM50 and
0.667 units⁄kg to 0.708 units⁄kg for human insulin
mix 50).
Safety
Insulin lispro mix 50 was generally well tolerated by
patients treated for 3 months. No death was reported
during this study. Three patients experienced one
serious adverse event (SAE) each causing their hospi-
talisation. One patient during LM50 treatment expe-
rienced pneumonia, while two patients during
human insulin mix 50 treatment experienced coro-
nary artery disease and hepatitis E respectively. All
three SAEs were regarded by the study investigators
to have no relationship with either the study drug or
device. Three patients in human insulin mix 50 treat-
ment discontinued from this study because of
adverse events of hepatitis E, hepatic cirrhosis and
angioneurotic oedema respectively. No patient in
LM50 treatment discontinued from this study
because of adverse events.
Similar numbers of patients experienced at least
one treatment-emergent adverse event (TEAE) in
each treatment group (39 in LM50 and 37 in human
insulin mix 50). The most common TEAEs reported
by patients were nasopharyngitis followed by hyperu-
ricaemia and then hypertension in both treatment
groups. Mean laboratory results for both treatment
groups at baseline and end-point were all within the
normal range. The mean changes in vital signs were
small and not considered clinically signiﬁcant.
Twenty-seven patients experienced at least one epi-
sode of hypoglycaemia in each treatment period. No
statistically signiﬁcant difference was found between
treatment groups for the incidence of hypoglycaemia
within patient (p = 0.828) nor in the rate of hypo-
glycaemia per 30 days (p = 0.401).
Discussion
This study compared the glucodynamics and safety
of premix formulations of insulin lispro and ILPS in
a 1 : 1 ratio (LM50) vs. human insulin mix 50, in a
twice a day regimen in a Chinese population. It was
important to compare these two insulin mixtures
because human insulin mix 50 has been widely pre-
scribed for patients in China, while LM50 is a newer
analogue formulation. The high-carbohydrate stan-
dard test meal in this study represents a high-carbo-
hydrate Chinese diet. With this meal, LM50 provided
better control of postprandial hyperglycaemia in
patients with diabetes; and during the 3-month treat-
ments, LM50 did not increase the incidence of hypo-
glycaemia compared with human insulin mix 50.
However, despite the improved PPBG with LM50,
HbA1c means were similar between the two insulin
treatments.
As with our results, Roach et al. (13) reported
improved postprandial glycaemic control and simi-
lar overall glycaemic control with insulin lispro
mixtures as compared with human insulin mix-
tures. In their study, patients received LM50 and
LM25 for the morning and evening meals, respec-
tively, as one treatment, and human insulin mix 50
and 30 for the morning and evening meals, respec-
tively, as the other treatment, for 3 months. Con-
trary to the equivalent rates of hypoglycaemia
between treatments in our study, they reported less
nocturnal hypoglycaemia with insulin lispro mix-
tures. Nocturnal hypoglycaemia was not assessed in
our study.
In the past, rapid-acting insulin lispro and the
basal insulin ILPS have been formulated in different
ratios in search of an optimal bolus-basal combina-
tion. Heise et al. (17) compared the pharmacokinetic
and pharmacodynamic proﬁles of various mix
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50% and 25% insulin lispro). That study suggested
increased insulin serum levels were achieved with
increasing proportions of insulin lispro in a linear
dose-dependent manner. Similarly, Schwartz et al.
(18) compared human insulin mix 30 with insulin
lispro mix 25 and LM50 in a test meal after a single
injection. They concluded insulin lispro mixtures
were associated with better PPBG control than
human insulin, and greater proportions of rapid-act-
ing insulin lispro within the mixture were associated
with better PPBG control. In another clinical trial,
LM50 provided better postprandial glycaemic control
after a test breakfast rich in carbohydrates compared
with a similar dose of insulin lispro mix 25. Speciﬁ-
cally, LM50 given before the standard breakfast was
found to be more effective in controlling the 2-h
PPBG and the 2-h PPBG excursion compared with
insulin lispro mix 25 given before the same meal.
The two treatments were found to be equivalent in
terms of FBG, HbA1c and incidence of hypoglyca-
emia (19).
Our results show that 1- and 2-h PPBG excursions
were signiﬁcantly better controlled with LM50 when
compared with those with human insulin mix 50. In
addition, LM50 provided signiﬁcantly lower mean 2-
h, but not 1-h, PPBG. Although, there was no signif-
icant change in FBG from baseline to end-point in
either treatment group, the slight increase in FBG
with LM50 and slight decrease with human insulin
mix 50 resulted in a statistically signiﬁcant difference
between groups at end-point. An explanation for this
difference in FBG results could be that the effect of
human insulin lasts longer than lispro and has some
overlap with human insulin isophane suspension for
the morning glucose.
Haemoglobin A1c was controlled equivalently with
both treatments in this study. In an effort to corre-
late our FBG and PPBG results with HbA1c, we ﬁnd
guidance from a trial by Monnier et al. (3), which
suggests that when HbA1c is in the range of 7.3–
8.4%, FBG and PPBG contribute equally to HbA1c.
In this study, the mean HbA1c values at end-point
for LM50 and human insulin mix 50 were 7.59%
and 7.61% respectively. So lower PPBG and higher
FBG with LM50 may result in an equivalent HbA1c
compared with human insulin. Thus, similar control
of HbA1c with both treatments perhaps reﬂects the
offsetting directions of PPBG and FBG between the
two treatments.
No signiﬁcant differences were observed between
treatment groups in insulin-dose requirements of
patients during the 12-week treatments. These
observations are consistent with those of another
12-week trial that compared glycaemic control with
ﬁxed mixtures containing insulin lispro mix 25 vs.
ﬁxed mixtures containing human insulin mix 30
(20).
The 1 : 1 ratio of mealtime and basal insulins may
not address needs associated with meals of all size
and composition. To achieve adequate glycaemic
control, insulins should be administered before each
meal, with three times a day, which is the most com-
mon frequency. The twice-daily regimen of 1 : 1
mixtures employed here may not be appropriate for
patients who consume three large meals per day.
Conclusively, LM50, well tolerated by patients
over the 3-month treatment period, may be an
appropriate substitute in patients who administer a
human insulin mixture. This 1 : 1 ratio of insulin
lispro and ILPS may provide similar HbA1c control
and better PPBG control compared with human
insulin mix 50 in insulin-requiring patients with
type 1 or type 2 diabetes while providing the con-
venience of injecting immediately before meals.
LM50 in a twice-a-day regimen may appeal to
patients who do not want to compromise their
high carbohydrate breakfast and dinner, and are
willing to cut down the number of injections
required per day.
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